Authors: Wexler, HM Molitoris, E Molitoris, D Finegold, SM

Citation: Hm. Wexler et al., In vitro activity of telithromycin (HMR 3647) against 502 strains of anaerobic bacteria, J ANTIMICRO, 47(4), 2001, pp. 467-469

Authors: Wexler, HM Molitoris, E Molitoris, D Finegold, SM

Citation: Hm. Wexler et al., In vitro activity of moxifloxacin against 179 strains of anaerobic bacteria found in pulmonary infections, ANAEROBE, 6(4), 2000, pp. 227-231

Authors: Sandler, RH Finegold, SM Bolte, ER Buchanan, CP Maxwell, AP Vaisanen, ML Nelson, MN Wexler, HM

Citation: Rh. Sandler et al., Short-term benefit from oral vancomycin treatment of regressive-onset autism, J CHILD NEU, 15(7), 2000, pp. 429-435

Authors: Wexler, HM Molitoris, D Finegold, SM

Citation: Hm. Wexler et al., In vitro activities of MK-826 (L-749,345) against 363 strains of anaerobicbacteria, ANTIM AG CH, 44(8), 2000, pp. 2222-2224

Authors: Wexler, HM Molitoris, E Molitoris, D Finegold, SM

Citation: Hm. Wexler et al., In vitro activity of HMR 3004 (RU 64004) against 502 strains of anaerobic bacteria, ANAEROBE, 5(2), 1999, pp. 65-68

Authors: Wexler, HM Finegold, SM

Citation: Hm. Wexler et Sm. Finegold, Current susceptibility patterns of anaerobic bacteria, YONSEI MED, 39(6), 1998, pp. 495-501